artículo académico

• A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice.  Oncotarget.  5:7843-7857. 2014
• Harnessing alveolar macrophages for sustained mucosal T-cell recall confers long-term protection to mice against lethal influenza challenge without clinical disease.  Mucosal Immunology.  7:89-100. 2014
• Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?.  Journal of OncoImmunology.  2:e26148. 2013
• Immune modulation by genetic modification of dendritic cells with lentiviral vectors.  Virus Research.  176:1-15. 2013
• PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy.  Oncoimmunology.  1:86-88. 2012
• On the Mechanism of T cell receptor down-modulation and its physiological significance.  The Journal of Bioscience and Medicine.  1:1-5. 2011
• PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8 + T cells.  EMBO Molecular Medicine.  3:581-592. 2011
• Selective Activation of Intracellular Signalling Pathways In Dendritic Cells For Cancer Immunotherapy.  Anti-cancer Agents in Medicinal Chemistry.  12:29-39. 2011
• Selective ERK Activation Differentiates Mouse and Human Tolerogenic Dendritic Cells, Expands Antigen-Specific Regulatory T Cells, and Suppresses Experimental Inflammatory Arthritis.  Arthritis & Rheumatology.  63:84-95. 2011
• Targeting Lentiviral Vectors for Cancer Immunotherapy.  Current Cancer Therapy Reviews.  7:248-260. 2011
• HIV-1 Lentiviral vector immunogenicity is mediated by Toll-Like Receptor 3 (TLR3) and TLR7.  Journal of Virology.  84:5627-5636. 2010